Raymond James Financial Services Advisors, Inc. Esperion Therapeutics, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$19.4 - $28.71 $167,519 - $247,910	-8,635 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$25.12 - $36.89 $17,960 - $26,376	715 Added 9.03%	8,635 $242,000
Q3 2020 Nov 04, 2020	SELL	$31.18 - $52.71 $182,403 - $308,353	-5,850 Reduced 42.48%	7,920 $294,000
Q2 2020 Jul 17, 2020	SELL	$30.04 - $51.31 $60,740 - $103,748	-2,022 Reduced 12.8%	13,770 $707,000
Q1 2020 Apr 21, 2020	BUY	$27.44 - $73.84 $85,914 - $231,193	3,131 Added 24.73%	15,792 $498,000
Q4 2019 Feb 12, 2020	BUY	$35.4 - $59.82 $7,080 - $11,964	200 Added 1.61%	12,661 $755,000
Q3 2019 Nov 07, 2019	SELL	$34.47 - $47.53 $5,963 - $8,222	-173 Reduced 1.37%	12,461 $457,000
Q2 2019 Aug 06, 2019	SELL	$40.1 - $52.33 $7,859 - $10,256	-196 Reduced 1.53%	12,634 $588,000
Q1 2019 May 06, 2019	SELL	$40.11 - $53.57 $19,653 - $26,249	-490 Reduced 3.68%	12,830 $515,000
Q4 2018 Feb 11, 2019	BUY	$36.99 - $59.11 $492,706 - $787,345	13,320 New	13,320 $613,000
Q2 2018 Jul 30, 2018	SELL	$36.2 - $76.4 $140,094 - $295,668	-3,870 Closed	0 $0
Q1 2018 Apr 16, 2018	BUY	$65.94 - $80.76 $33,299 - $40,783	505 Added 15.01%	3,870 $280,000
Q4 2017 Feb 09, 2018	BUY	$43.47 - $67.43 $146,276 - $226,901	3,365	3,365 $222,000

Others Institutions Holding ESPR

# of Institutions

207

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $202M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account